Bafna Pharmaceuticals Limited (BAFNAPH.NS)
INR 72.5
(0.0%)
INR 72.5
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.52 Billion INR | 32.18% |
| 2022 | 1.15 Billion INR | 35.48% |
| 2021 | 851.4 Million INR | 19.55% |
| 2020 | 712.17 Million INR | 67.68% |
| 2019 | 424.72 Million INR | -2.04% |
| 2018 | 433.58 Million INR | -8.08% |
| 2017 | 471.7 Million INR | -27.39% |
| 2016 | 649.61 Million INR | -23.86% |
| 2015 | 853.18 Million INR | -12.65% |
| 2014 | 976.74 Million INR | -47.3% |
| 2013 | 1.85 Billion INR | 5.44% |
| 2012 | 1.75 Billion INR | 39.88% |
| 2011 | 1.25 Billion INR | 23.29% |
| 2010 | 1.01 Billion INR | 35.57% |
| 2009 | 751.81 Million INR | 59.1% |
| 2008 | 472.53 Million INR | 19.31% |
| 2007 | 396.06 Million INR | 6.34% |
| 2006 | 372.46 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 332.86 Million INR | -19.59% |
| 2023 Q2 | 406.78 Million INR | -3.03% |
| 2023 Q4 | 413.98 Million INR | 45.55% |
| 2023 FY | 1.52 Billion INR | 32.18% |
| 2023 Q3 | 284.42 Million INR | -30.08% |
| 2023 Q1 | 419.47 Million INR | -0.7% |
| 2022 FY | 1.15 Billion INR | 35.48% |
| 2022 Q1 | 169.26 Million INR | 12.98% |
| 2022 Q2 | 219.6 Million INR | 29.74% |
| 2022 Q3 | 342.18 Million INR | 55.82% |
| 2022 Q4 | 422.43 Million INR | 23.45% |
| 2021 Q4 | 149.82 Million INR | -26.77% |
| 2021 Q1 | 212.58 Million INR | -2.66% |
| 2021 FY | 851.4 Million INR | 19.55% |
| 2021 Q2 | 284.39 Million INR | 33.78% |
| 2021 Q3 | 204.6 Million INR | -28.06% |
| 2020 Q1 | 167.02 Million INR | 27.18% |
| 2020 FY | 712.17 Million INR | 67.68% |
| 2020 Q4 | 218.4 Million INR | 24.98% |
| 2020 Q3 | 174.75 Million INR | 14.97% |
| 2020 Q2 | 151.99 Million INR | -9.0% |
| 2019 Q1 | 68.49 Million INR | -69.65% |
| 2019 FY | 424.72 Million INR | -2.04% |
| 2019 Q4 | 131.32 Million INR | 20.21% |
| 2019 Q3 | 109.25 Million INR | -5.53% |
| 2019 Q2 | 115.65 Million INR | 68.85% |
| 2018 Q2 | 88.37 Million INR | -15.21% |
| 2018 FY | 433.58 Million INR | -8.08% |
| 2018 Q4 | 225.69 Million INR | 72.62% |
| 2018 Q3 | 130.74 Million INR | 47.94% |
| 2018 Q1 | 104.23 Million INR | 0.0% |
| 2017 FY | 471.7 Million INR | -27.39% |
| 2016 FY | 649.61 Million INR | -23.86% |
| 2015 FY | 853.18 Million INR | -12.65% |
| 2014 FY | 976.74 Million INR | -47.3% |
| 2013 FY | 1.85 Billion INR | 5.44% |
| 2012 Q1 | 341.15 Million INR | 0.0% |
| 2012 Q2 | 521.18 Million INR | 52.77% |
| 2012 Q3 | 259.9 Million INR | -50.13% |
| 2012 Q4 | 592.96 Million INR | 128.14% |
| 2012 FY | 1.75 Billion INR | 39.88% |
| 2011 FY | 1.25 Billion INR | 23.29% |
| 2010 FY | 1.01 Billion INR | 35.57% |
| 2009 FY | 751.81 Million INR | 59.1% |
| 2008 FY | 472.53 Million INR | 19.31% |
| 2007 FY | 396.06 Million INR | 6.34% |
| 2006 FY | 372.46 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 97.506% |
| Hester Biosciences Limited | 3.04 Billion INR | 49.937% |
| Aarti Drugs Limited | 25.28 Billion INR | 93.97% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 91.602% |
| Albert David Limited | 3.62 Billion INR | 57.936% |
| Alembic Limited | 1.57 Billion INR | 3.187% |
| Alkem Laboratories Limited | 126.67 Billion INR | 98.796% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 67.795% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -280.828% |
| Brooks Laboratories Limited | 794.86 Million INR | -91.814% |
| Eris Lifesciences Limited | 20.09 Billion INR | 92.411% |
| FDC Limited | 19.42 Billion INR | 92.153% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 93.322% |
| Gufic Biosciences Limited | 8.06 Billion INR | 81.099% |
| Hikal Limited | 17.84 Billion INR | 91.457% |
| Ind-Swift Limited | 5.02 Billion INR | 69.657% |
| Innova Captab Limited | 10.81 Billion INR | 85.9% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 92.851% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 26.946% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 97.725% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | 73.738% |
| Lupin Limited | 196.56 Billion INR | 99.224% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | 58.496% |
| Medico Remedies Limited | 1.44 Billion INR | -5.206% |
| Morepen Laboratories Limited | 17.01 Billion INR | 91.041% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 90.949% |
| Orchid Pharma Limited | 8.19 Billion INR | 81.392% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 86.757% |
| RPG Life Sciences Limited | 5.82 Billion INR | 73.805% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | 1.235% |
| Sigachi Industries Limited | 3.98 Billion INR | 61.784% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 87.688% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 85.498% |
| Themis Medicare Limited | 3.81 Billion INR | 60.063% |
| Unichem Laboratories Limited | 16.57 Billion INR | 90.801% |
| Vaishali Pharma Limited | 862.79 Million INR | -76.711% |
| Wanbury Limited | 5.75 Billion INR | 73.514% |
| Windlas Biotech Limited | 6.3 Billion INR | 75.836% |
| ZIM Laboratories Limited | 3.67 Billion INR | 58.515% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 88.097% |
| Ipca Laboratories Limited | 77.05 Billion INR | 98.021% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.686% |
| Venus Remedies Limited | 5.91 Billion INR | 74.222% |
| Sakar Healthcare Limited | 1.54 Billion INR | 1.104% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 99.474% |
| Divi's Laboratories Limited | 78.45 Billion INR | 98.057% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 88.231% |
| Mankind Pharma Limited | 103.34 Billion INR | 98.525% |
| Sequent Scientific Limited | 13.69 Billion INR | 88.869% |
| Laurus Labs Limited | 50.01 Billion INR | 96.952% |
| Neuland Laboratories Limited | 15.58 Billion INR | 90.218% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 95.578% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 98.709% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.198% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 63.805% |
| Wockhardt Limited | 27.89 Billion INR | 94.533% |
| Bal Pharma Limited | 3.39 Billion INR | 55.054% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.454% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 80.206% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -59.416% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 90.907% |
| Shilpa Medicare Limited | 11.53 Billion INR | 86.778% |
| Valiant Laboratories Limited | 1.82 Billion INR | 16.254% |
| Ajanta Pharma Limited | 42.08 Billion INR | 96.377% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | 61.461% |
| Granules India Limited | 45.06 Billion INR | 96.617% |
| Medicamen Biotech Limited | 1.79 Billion INR | 14.969% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 41.188% |
| Piramal Enterprises Limited | 60.33 Billion INR | 97.473% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 98.562% |
| NATCO Pharma Limited | 40.02 Billion INR | 96.19% |
| Suven Life Sciences Limited | 116.92 Million INR | -1203.917% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -202.382% |
| Strides Pharma Science Limited | 40.51 Billion INR | 96.236% |
| Indoco Remedies Limited | 18.17 Billion INR | 91.61% |
| Alpa Laboratories Limited | 1.08 Billion INR | -40.213% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -46.131% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -101.82% |